NCT06266299 - A Study of KK2269 in Adult Participants With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Solid TumorMetastatic Solid TumorGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaNon Small Cell Lung Cancer

Interventions

DRUG

KK2269

KK2269 administered intravenously

DRUG

Docetaxel

antineoplastic drug administered intravenously

Trial Locations (6)

91010

RECRUITING

City Of Hope, Duarte

92663

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

464-8681

RECRUITING

Aichi Cancer Center, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku

135-8550

RECRUITING

Cancer Institute Hospital of JFCR, Koto-Ku